 | |
| Clinical data | |
|---|---|
| Pronunciation | dak" oh mi' ti nib |
| Trade names | Vizimpro |
| Other names | PF-00299804 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618055 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Protein binding | 98% |
| Metabolism | CYP2D6,CYP3A4 |
| Metabolites | O-desmethyl-dacomitinib |
| Eliminationhalf-life | 70 hrs |
| Excretion | 79% faeces, 3% urine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H25ClFN5O2 |
| Molar mass | 469.95 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dacomitinib, sold under the brand nameVizimpro, is amedication for the treatment ofnon-small-cell lung carcinoma (NSCLC). It is a selective andirreversible inhibitor ofEGFR.[3]
Dacomitinib has advanced to severalPhase III clinical trials. In January 2014, results of the first trials were disappointing, with a failure to meet the study goals,[4][5][6] but additional Phase III trials continued.[4] In 2017, results of a trial comparing dacomitinib togefitinib for NSCLC (driven by mutated EGFR) were announced.[7]
Dacomitinib was approved for medical use in the United States in September 2018,[8] in Japan in 2019, and in the European Union in 2019;[9] for the treatment ofnon-small cell lung cancer withepidermal growth factor receptor (EGFR) gene mutation.
